TL;DR
Tongkat Ali (Eurycoma longifolia) is a Malaysian herbal adaptogen with the strongest evidence for male idiopathic infertility (200 mg/day, 3–9 months; +65.5% sperm concentration, +94.9% morphology) and cortisol reduction in stressed/older adults (−16% at 200 mg/day × 4 weeks; Talbott 2013 PMID 23705671). Testosterone elevation is statistically confirmed (meta-analysis SMD=1.352, p=0.001; PMID 36013514) but mechanism is NOT via LH/FSH (PMID 33559971) — likely secondary to cortisol reduction. Erectile function is NOT established (meta-analysis PMID 26365449 — null). Benefits are population-specific: null data in exercise-trained individuals (2024 MDPI Applied Sciences). Safety concerns are real: EFSA genotoxicity flag (PMC8693240), LiverTox D rating, confirmed propranolol interaction (PMID 21054461), and 26% product mercury contamination (PMID 16567029). No pharmacopeial standard exists.
Why It Matters for Vitals
Tongkat Ali intersects three Vitals coaching domains:
- Cortisol–HRV axis — cortisol reduction should improve morning HRV and sympathetic recovery; population specificity matters critically for fit users
- Body composition — testosterone elevation without HPG stimulation is mechanistically distinct from pharmaceutical TRT; implications for coaching logic around “testosterone boosting”
- Male fertility coaching — the most evidence-backed clinical indication; directly actionable in Vitals coaching for male fertility clients
Wearables: No Tongkat Ali-specific wearable validation exists. HRV, resting HR, and sleep efficiency trends are reasonable proxy monitors. Cortisol is not directly measurable by consumer wearables.
Key Facts
| Property | Value |
|---|---|
| Common names | Tongkat Ali, Longjack, Malaysian Ginseng |
| Active compounds | Eurycomanone (~1%), eurypeptides/glycosaponins, 9-methoxycanthin-6-one |
| Primary mechanisms | HPA-axis cortisol modulation; non-LH/FSH testosterone elevation |
| Evidence-backed doses | 200 mg/day (cortisol, fertility); 200–400 mg/day (testosterone in older/stressed) |
| Key duration | ≥4 weeks for cortisol; 3–9 months for fertility |
| Evidence gap | No human oral bioavailability data; no long-term (>6 month) safety RCTs |
| Product quality risk | Major — no pharmacopeial standard; ratio claims (100:1, 200:1) implausible; Informed Sport certification the minimum bar |
Mechanism Summary
Cortisol reduction (HPA-axis modulation): Tongkat Ali reduces cortisol via HPA-axis modulation — the more consistent and mechanistically plausible primary pathway. Lower cortisol reduces catabolic antagonism at the androgen receptor, improving the anabolic milieu.
Testosterone elevation — non-HPG mechanism: In a young male RCT (PMID 33559971), Tongkat Ali raised testosterone without raising LH or FSH. This rules out HPG-axis stimulation. Possible mechanisms:
- Reduced SHBG binding (free testosterone increased via SHBG decline)
- Direct Leydig cell stimulation
- Aromatase or 5α-reductase inhibition (unconfirmed in humans)
Critical implication: Since the testosterone effect is NOT LH/FSH-mediated, it is likely secondary to cortisol/HPA modulation. This explains why it works in stressed/older populations but shows null results in already-fit athletes with low baseline cortisol.
Male fertility: May involve FSH-like activity on Sertoli cells, improving spermatogenesis independently of the testosterone mechanism.
Sperm quality (PMID 33559971; PMC3739276): 200 mg/day × 9 months → +65.5% sperm concentration, +94.9% normal morphology, 14.7% pregnancy rate.
Eurycomanone PK (rats, PMID 16206032, PMID 29997335):
- Oral bioavailability: ~10–11%
- IV half-life: ~0.3–1.0 h
- Tmax: ~4.4 h
- Poor membrane permeability; NOT due to gastric acid instability
- CYP inhibition: eurycomanone does NOT inhibit major CYP enzymes (IC50 >250 µg/mL); crude extract weakly inhibits CYP1A2/2A6/2C19
What the Current Evidence Suggests
| Outcome | Evidence | Grade | Notes |
|---|---|---|---|
| Cortisol reduction (stressed adults) | −16% at 200 mg/day × 4 wks | Supported | Talbott 2013 PMID 23705671 |
| Cortisol reduction (exercise-trained) | Null | Contested | 2024 MDPI Applied Sciences |
| Testosterone elevation (meta) | SMD=1.352, p=0.001 | Confirmed | PMID 36013514; population-dependent |
| Testosterone elevation (non-LH/FSH) | No LH/FSH change; testosterone ↑ | Supported | PMID 33559971 |
| Strength in elderly | Handgrip ↑ at 400 mg/day × 5 wks | Supported | PMID 23754792 |
| Strength in athletes | Null | Contested | 2024 MDPI Applied Sciences; PMID 37398958 |
| Male idiopathic infertility | +65.5% concentration; +94.9% morphology | Supported | PMC3739276; open-label, no placebo |
| Erectile function | No significant effect | NOT ESTABLISHED | PMID 26365449 meta-analysis |
| Mood/stress (short-term) | Tension −11%, Anger −12%, Confusion −15% | Supported | Talbott 2013 POMS |
| Long-term mood/QoL | Null | Contested | PMC6294837; confounded by multivitamins |
Likely Wearable / Vitals Relevance
All biometric mappings are proxy or speculative. Human sign-off required before clinical use.
| Metric | Direction | Confidence | Basis |
|---|---|---|---|
| Morning HRV | ↑ | Medium | Cortisol reduction → reduced sympathetic suppression. Talbott 2013 cortisol data is the basis. No TA-specific wearable RCT. |
| Resting heart rate | ↓ | Medium | Reduced cortisol → lower sympathetic tone. No direct evidence. |
| Sleep latency / efficiency | ↑ | Low | Cortisol reduction should improve sleep onset. Extrapolated from cortisol–sleep physiology. No direct sleep architecture data for TA. |
| Cortisol proxy (morning readiness composite) | ↓ | Medium | Talbott used salivary cortisol; Apple Watch has no cortisol sensor. HRV + RHR + sleep composite as proxy is inferential. |
| Training HRV recovery | ↑ | Low | Cortisol reduction should improve post-exercise autonomic recovery. No direct evidence. |
Coaching recommendation: If using Tongkat Ali, track morning HRV trends, resting HR, and sleep efficiency as proxy indicators. Do not use body composition metrics alone to assess effectiveness. Cycle off every 4–6 weeks. Use Informed Sport batch-tested brands only.
Risks and Uncertainty
Safety concerns
| Risk | Severity | Source |
|---|---|---|
| Genotoxicity (EFSA flag) | Severe — regulatory | PMC8693240; EFSA 2021 novel food assessment |
| Hepatotoxicity (LiverTox D rating) | Intermediate | LiverTox NBK609015; ALT 876, AST 445 U/L case reports |
| Mercury contamination | Intermediate — sourcing | 26% of 100 Malaysian products exceeded 0.5 ppm; PMID 16567029 |
| Propranolol interaction | Confirmed | −29% AUC, −42% Cmax; PMID 21054461; separate by 2–4 hours |
| CYP interaction (crude extract) | Theoretical | Weak CYP1A2/2A6/2C19 inhibition at high doses; in vitro only |
Contraindications
- Pregnant and lactating women — EFSA novel food assessment
- Pre-existing liver disease — excluded from trials; possible higher risk
- Propranolol users — separate dosing by 2–4 hours minimum
Evidence gaps
- No human oral bioavailability data — all PK is animal
- No long-term (>6 month) human safety RCTs — longest is 12 weeks
- No DXA/BIA body composition RCTs — strength data is handgrip only
- No RCT data in women — NCT05846993 registered but unpublished
- No RCT data for Tongkat Ali + GLP-1 co-administration
- No validated product biomarker — eurycomanone is a marker, not necessarily the active compound
Best Stack Context
For cortisol/HPA optimization: Compare to Ashwagandha (stronger cortisol data, multiple RCTs) or Rhodiola rosea (stimulating adaptogen, CRF1 antagonism). Ashwagandha has the stronger evidence base for cortisol; Tongkat Ali has a distinct fertility indication.
For male fertility: No direct adaptogen comparison — fertility benefit is Tongkat Ali’s most differentiated indication.
For body recomposition (GLP-1 context): Tongkat Ali cortisol reduction may be complementary during caloric deficit. No direct interaction with Retatrutide or GHK-Cu documented. Monitor for additive GI effects.
For athletes: Null data in exercise-trained individuals (2024 MDPI) — Creatine, Ashwagandha, or Vitamin D3 K2 have more applicable evidence for strength/body composition in trained populations.
Cycling: Common practice (4 weeks on / 1 week off, or 5 days on / 2 days off) has no clinical trial backing. Based on supplement community consensus.
Related Notes
MOC
Hub notes
- Ashwagandha — stronger cortisol RCT database; no fertility indication
- Rhodiola rosea — stimulating adaptogen; different mechanism (CRF1/monoamine)
- Creatine — athlete body composition; applicable evidence in trained populations
- Vitamin D3 K2 — hormone/metabolic baseline stack
Mechanisms
- BDNF NGF induction — neuroplasticity pathway shared with Ashwagandha, Bacopa, Rhodiola
- HPA-axis modulation — shared adaptogen mechanism
Biometrics
- HRV — primary wearable proxy for Tongkat Ali monitoring
- HRV signatures — baseline for interpretation
- Sleep architecture — sleep proxy interpretation context
Risk notes
- Stress Cortisol Optimization — cortisol-HRV axis, HRV biofeedback, coaching logic
Detection
- No Tongkat Ali-specific detection model exists; HRV/sleep proxies are inferential only